Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study

Harm Reduction Journal

Ryan P Westergaard⁶  John J Fangman¹  Scott Stokes⁴  Shawnika J Hull³  Meghan B Brennan²  Joshua A Barocas⁵ 

[1] Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA;William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA;School of Journalism and Mass Communication, University of Wisconsin - Madison, 821 University Ave, 5115 Vilas Hall, Madison, WI 53706, USA;AIDS Resource Center of Wisconsin, 3716 W. Wisconsin Ave, Milwaukee, WI 53208, USA;Department of Medicine, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, UWMFCB 5th floor, Madison, WI 53705, USA;Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, 707 WARF Building, 610 North Walnut St, Madison, WI 53726, USA

关键词: Health care access;    Stigma;    Injection drug use;    Screening;    Hepatitis C;   

Others  :  809750
DOI  :  10.1186/1477-7517-11-1

 received in 2013-10-06, accepted in 2014-01-10,  发布年份 2014

【 摘 要 】

Background

People who inject drugs (PWID) are at high risk of contracting and transmitting and hepatitis C virus (HCV). While accurate screening tests and effective treatment are increasingly available, prior research indicates that many PWID are unaware of their HCV status.

Methods

We examined characteristics associated with HCV screening among 553 PWID utilizing a free, multi-site syringe exchange program (SEP) in 7 cities throughout Wisconsin. All participants completed an 88-item, computerized survey assessing past experiences with HCV testing, HCV transmission risk behaviors, and drug use patterns. A subset of 362 clients responded to a series of open-ended questions eliciting their perceptions of barriers and facilitators to screening for HCV. Transcripts of these responses were analyzed qualitatively using thematic analysis.

Results

Most respondents (88%) reported receiving a HCV test in the past, and most of these (74%) were tested during the preceding 12 months. Despite the availability of free HCV screening at the SEP, fewer than 20% of respondents had ever received a test at a syringe exchange site. Clients were more likely to receive HCV screening in the past year if they had a primary care provider, higher educational attainment, lived in a large metropolitan area, and a prior history of opioid overdose. Themes identified through qualitative analysis suggested important roles of access to medical care and prevention services, and nonjudgmental providers.

Conclusions

Our results suggest that drug-injecting individuals who reside in non-urban settings, who have poor access to primary care, or who have less education may encounter significant barriers to routine HCV screening. Expanded access to primary health care and prevention services, especially in non-urban areas, could address an unmet need for individuals at high risk for HCV.

【 授权许可】

   
2014 Barocas et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Colvin HM, Mitchell AE, Institute of Medicine (U.S.), Committee on the Prevention and Control of Viral Hepatitis Infections, Institute of Medicine (U.S.), Board on Population Health and Public Health Practice: Hepatitis and liver cancer a national strategy for prevention and control of hepatitis B and C. Washington, DC: National Academies Press; 2010.
• [2]Islam MM, Topp L, Day CA, Dawson A, Conigrave KM: The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. Int J Drug Policy 2012, 23(2):94-102.
• [3]Weinbaum C, Lyerla R, Margolis HS: Centers for disease control and prevention: prevention and control of infections with hepatitis viruses in correctional settings. Centers for disease control and prevention. MMWR Recomm Rep 2003, 52(RR-1):1-36.
• [4]Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, Des Jarlais D, Williams IT: Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis 2008, 46(12):1852-1858.
• [5]Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C: Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008, 168(10):1099-1109.
• [6]Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL: Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008, 33(3):126-133.
• [7]Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS: Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006, 121(6):710-719.
• [8]Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douihy A, Mandler RN, Sorenson JL, Colfax G, McCarty D, Cohen SE, Penn PE, Lape D, Metsch LR: Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. Addict Behav 2012, 37(4):552-555.
• [9]Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinblum CM: The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012, 156(4):263-270.
• [10]Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V: Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011, 45(2):e17-e24.
• [11]Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206.
• [12]Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo C-G, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW: Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 2012, 61:1-32.
• [13]Rosenstock IM: Why people use health services. Milbank Mem Fund Q 1966, 44(3):Suppl:94-127.
• [14]Rosenstock IM, Strecher VJ, Becker MH: Social learning theory and the health belief model. Health Educ Q 1988, 15(2):175-183.
• [15]Rosenstock IM: Historical origins of the health belief model. Health Educ Monogr 1974, 2:328-335.
• [16]Boyatzis RE: Transforming qualitative information: thematic analysis and code development. Thousand Oaks, CA: Sage Publications; 1998.
• [17]Fereday J, Muir-Cochrane E: Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods 2006, 5:80-92.
• [18]Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, Keaveney M, Lambert J, McCormick PA, McKiernan S, Moloney J, Perry N, Cullen W: Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010, 24(12):753-762.
• [19]Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, Guzman L, Kletter E, Seewald RM, Des-Jarlais DC, Sorensen JL, Perlman DC: Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm Reduct J 2013, 10:10. BioMed Central Full Text
• [20]Hughes R: “Getting checked and having the test”: drug injectors’ perceptions of HIV testing - findings from qualitative research conducted in England. Eur Addict Res 2002, 8(2):94-102.
• [21]Inungu JN, Quist-Adade C, Beach EM, Cook T, Lamerato M: Shift in the reasons why adults seek HIV testing in the United States: policy implications. AIDS Read 2005, 15(1):35-38. 42
• [22]Kellerman SE, Lehman JS, Lansky A, Stevens MR, Hecht FM, Bindman AB, Wortley PM: HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing. J Acquir Immune Defic Syndr 2002, 31(2):202-210.
• [23]Strauss SM, Munoz-Plaza C, Tiburcio NJ, Astone-Twerell J, Des Jarlais DC, Gwadz M, Hagan H, Osborne A, Rosenblum A: Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. J Drug Issues 2008, 38(4):1161-1185.
• [24]Miller WR, Rollnick S: Motivational interviewing: helping people change. New York, NY: Guilford Press; 2013.
• [25]Tompkins CN, Wright NM, Jones L: Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Br J Gen Pract 2005, 55(513):263-268.
• [26]Treloar CJ, Hopwood MN, Loveday SK: Hepatitis C-related discrimination in healthcare. Report of the third Australasian conference on hepatitis C, Melbourne, march 202. Med J Aust 2002, 177(5):233-234.
• [27]Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR: “They treated me like a leper”. Stigmatization and the quality of life of patients with hepatitis C. C J Gen Intern Med 2003, 18(10):835-844.
• [28]Grebely J, Matthews GV, Lloyd AR, Dore GJ: Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis 2013, 57(7):1014-1020.
• [29]Wright NMJ, Tompkins CNE, Jones L: Exploring risk perception and behaviour of homeless injecting drug users diagnosed with hepatitis C. Health Soc Care Community 2005, 13(1):75-83.
• [30]Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, Hellard ME: Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? analysis of the networks II study. Int J Drug Policy 2013, S0955–3959(13):00129-1.